More Articles

Biosimilars and cancer drug shortages in Europe Pharma News | Posted 18/11/2011

With all the talk about drug shortages in the US it might be easy to forget the rest of the world, but it seems that drug shortages are also hitting European countries and are affecting not just ge...

Bill to outlaw pay-to-delay moves ahead slowly Policies & Legislation | Posted 18/11/2011

A bill banning pay-to-delay, the practice by which originator and generics firms share the profit from drugs coming off patent rather than moving quickly to price reduction, is progressing slowly t...

Speed to market critical in biosimilar development Biosimilars/General | Posted 18/11/2011

For companies looking to develop biosimilars speed to market is critical, but this must not be done by sacrificing product quality, according to a report from Contract Research Organisation (CRO) Q...

Generic atorvastatin partnership Generics/News | Posted 18/11/2011

In early November 2011, there has been speculation that Ranbaxy Laboratories and Teva are about to join in manufacturing generic atorvastatin, better known as Lipitor, in the US.

FDA definitions of generics and biosimilars Biosimilars/General | Posted 18/11/2011

Confusion surrounding terms used in the global field of generics and biosimilars is a recognised problem.The source of some of this confusion is due to authorities in various regions of the world d...

US biosimilars: many barriers to overcome Biosimilars/Research | Posted 18/11/2011

EMA has been successful in devising a system for authorising the marketing of biosimilar products and 14 biosimilars are currently on the market in the major countries of the EU [1]. Generally, bio...

Stada to buy Spirig’s generics business Generics/News | Posted 18/11/2011

German generics giant Stada Arzneimittel announced on 9 November 2011 that it had signed a deal to buy Switzerland-based Spirig Pharma’s generics business for approximately Euros 78 million.

Natco snaps up biosimilars: signing deal with Mabxience Biosimilars/News | Posted 18/11/2011

Indian generic drugmaker Natco Pharma announced that it had entered into an exclusive agreement with Mabxience, the biosimilar division of Swiss firm Chemo Sa Lugano, on 19 September 2011.